Related Experiment Videos
Acute troglitazone action in isolated perfused rat liver
K Preininger1, H Stingl, R Englisch
1Department of Internal Medicine III, University of Vienna, Austria.
British Journal of Pharmacology
|March 2, 1999
Summary
Troglitazone, a type 2 diabetes drug, affects liver function by altering glucose and lactate metabolism and bile secretion. These effects, including increased lactate and portal pressure, are dose-dependent and may be influenced by albumin.
Area of Science:
- Hepatology
- Endocrinology
- Pharmacology
Background:
- Troglitazone is a thiazolidinedione compound used to treat type 2 diabetes by improving insulin sensitivity.
- The impact of thiazolidinediones on liver function requires further investigation.
Purpose of the Study:
- To investigate the acute effects of troglitazone on liver function in isolated perfused rat livers.
- To determine troglitazone's influence on hepatic glucose and lactate fluxes, bile secretion, and portal pressure under various hormonal conditions.
Main Methods:
- Isolated perfused rat liver model.
- Administration of varying doses of troglitazone (0.61 and 3.15 microM) under basal, insulin-, and/or glucagon-stimulated conditions.
- Measurement of hepatic glucose and lactate fluxes, bile secretion, and portal pressure.
Main Results:
- High-dose troglitazone inhibited glucagon-stimulated glucose production and bile secretion, while increasing basal glucose production and lactate release.
- Low-dose troglitazone increased lactate release and portal venous pressure.
- Albumin addition appeared to blunt some of troglitazone's hepatic effects.
Conclusions:
- Troglitazone exerts complex hepatic effects, including both insulin-like and non-insulin-like actions.
- These effects are dose-dependent and can significantly alter glucose and lactate metabolism and bile secretion.
- The interaction with albumin suggests a potential role in modulating troglitazone's in vivo activity.